Annual Recurring Revenue (ARR)⁽¹⁾ up 75% YoY to $93.7 million
Total Revenue up 94% YoY to $32.0 million
Adjusted EBITDA⁽¹⁾ up 58% YoY to $7.2 million
TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three and nine months ended September 30, 2025 with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedarplus.com.
“In the third quarter, we achieved annual organic ARR⁽¹⁾ growth of 15% and 22% adjusted EBITDA⁽¹⁾ as a percent of revenue,” said Dan Matlow, CEO of VitalHub. “Completed project deliveries exceeded our expectations from a services revenue perspective, while recurring revenue trends continued to track positively. We are optimizing the commercial and operational alignment of Novari and Induction. Our primary focus is integrating our most recent acquisitions and enhancing margins while continuing to pursue new opportunities.”
VitalHub’s quarterly investor conference call will take place on Friday, November 7, 2025, at 9:00AM EST. To register for the conference call please visit: https://us06web.zoom.us/webinar/register/WN_CDYke6WeQXGh1QeEQ4xrqg
Third Quarter 2025 Highlights
- ARR⁽¹⁾ as at September 30, 2025 was $93,693,789 as compared to $79,589,081 at June 30, 2025, an increase of $14,104,708 or 18%.
Over the previous quarter, ARR⁽¹⁾ movement in Q3 2025 from Q2 2025 was attributable to the following:- Organic growth of $1,711,335 or 2%.
- Acquisition growth of $12,000,000 or 15%.
- Gain of $393,373 due to fluctuations in foreign exchange rates.
- Revenue of $32,044,030 as compared to $16,509,135 in the equivalent prior year period, an increase of $15,534,895 or 94%.
- Gross profit as a percentage of revenue was 81% in Q3 2025 and Q3 2024.
- Net income before income taxes of $1,586,383 as compared to $2,360,258 in the equivalent prior year period, a decrease of $773,875 or 33%.
- EBITDA⁽¹⁾ of $4,777,351 as compared to $3,004,034 in the equivalent prior year period, an increase of $1,773,317 or 59%.
- Adjusted EBITDA⁽¹⁾ of $7,206,257 or 22% of revenue, as compared to $4,554,597 or 28% of revenue in the equivalent prior year period, an increase of $2,651,660 or 58%.
Nine Month 2025 Highlights
- ARR⁽¹⁾ as at September 30, 2025 was $93,693,789 as compared to $53,452,108 at September 30, 2024, an increase of $40,241,681 or 75%.
Over the previous year, ARR⁽¹⁾ movement in Q3 2025 from Q3 2024 was attributable to the following:- Organic growth of $7,959,283 or 15%.
- Acquisition growth of $30,470,000 or 57%.
- Gain of $1,812,398 due to fluctuations in foreign exchange rates.
- Revenue of $77,576,544 as compared to $48,003,531 in the equivalent prior year period, an increase of $29,573,013 or 62%.
- Gross profit as a percentage of revenue was 81% in the first nine months of 2025 and 2024.
- Net income before income taxes of $5,329,022 as compared to net income before income taxes of $5,722,758 in the equivalent prior year period, a decrease of $393,736 or 7%.
- EBITDA⁽¹⁾ of $11,527,408 compared to $8,075,502 in the prior year, an increase of $3,451,906 or 43%.
- Adjusted EBITDA⁽¹⁾ of $19,125,590 or 25% of revenue, compared to $12,793,514 or 27% of revenue in the equivalent prior year period, an increase of $6,332,076 or 49%.
- Cash on hand as at September 30, 2025 was $123,684,500 compared to $56,574,904 as at December 31, 2024.
(1) Non-IFRS measure. Disclaimers and reconciliations can be found in SEDAR filings.
Selected Financial Information
| | Three months ended | Nine months ended |
| | September 30, 2025 | % Revenue | September 30, 2024 | % Revenue | Change | September 30, 2025 | % Revenue | September 30, 2024 | % Revenue | Change |
| | $ | | $ | | % | $ | | $ | | % |
| Revenue | 32,044,030 | | 100% | 16,509,135 | | 100% | 94% | 77,576,544 | | 100% | 48,003,531 | | 100% | 62% |
| | | | | | | | | | | |
| Cost of sales | 6,162,109 | | 19% | 3,215,845 | | 19% | (92%) | 14,892,110 | | 19% | 9,258,338 | | 19% | (61%) |
| | | | | | | | | | | |
| Gross profit | 25,881,921 | | 81% | 13,293,290 | | 81% | 95% | 62,684,434 | | 81% | 38,745,193 | | 81% | 62% |
| | | | | | | | | | | |
| Operating expenses | | | | | | | | | | |
| General and administrative | 6,485,230 | | 20% | 3,555,539 | | 22% | (82%) | 16,433,883 | | 21% | 10,008,360 | | 21% | (64%) |
| Sales and marketing | 2,883,744 | | 9% | 1,562,915 | | 9% | (85%) | 7,608,691 | | 10% | 5,081,213 | | 11% | (50%) |
| Research and development | 9,237,648 | | 29% | 3,943,697 | | 24% | (134%) | 20,490,859 | | 26% | 11,037,178 | | 23% | (86%) |
| Depreciation of property and equipment | 155,054 | | 0% | 93,687 | | 1% | (66%) | 547,992 | | 1% | 252,691 | | 1% | (117%) |
| Depreciation of right-of-use assets | 175,720 | | 1% | 108,905 | | 1% | (61%) | 401,115 | | 1% | 326,912 | | 1% | (23%) |
| Share-based compensation | 647,324 | | 2% | 636,177 | | 4% | (2%) | 2,057,535 | | 3% | 1,660,430 | | 3% | (24%) |
| Deferred share-based compensation | 0 | | 0% | 0 | | 0% | 0% | 90,000 | | 0% | 0 | | 0% | (100%) |
| Foreign currency loss (gain) | 69,042 | | 0% | (323,458 | ) | (2%) | 121% | (978,659 | ) | (1%) | (175,072 | ) | (0%) | (459%) |
| | | | | | | | | | | |
| Other expenses (income) | | | | | | | | | | |
| Amortization of intangible assets | 3,315,437 | | 10% | 1,197,953 | | 7% | (177%) | 6,674,571 | | 9% | 3,418,794 | | 7% | (95%) |
| Business acquisition, restructuring and integration costs | 3,204,291 | | 10% | 841,454 | | 5% | (281%) | 6,637,858 | | 9% | 2,652,758 | | 6% | (150%) |
| (Gain) loss on change in fair value of contingent consideration | (1,245,000 | ) | (4%) | 72,932 | | 0% | 1807% | (1,009,502 | ) | (1%) | 404,824 | | 1% | 349% |
| Interest expense (net of interest income) | (481,136 | ) | (2%) | (766,046 | ) | (5%) | (37%) | (1,479,009 | ) | (2%) | (1,680,448 | ) | (4%) | (12%) |
| Interest expense from lease liabilities | 25,893 | | 0% | 9,277 | | 0% | (179%) | 53,717 | | 0% | 34,795 | | 0% | (54%) |
| Loss on disposal of property and equipment | 0 | | 0% | 0 | | 0% | 0% | 4,070 | | 0% | 0 | | 0% | (100%) |
| | | | | | | | | | | |
| Current and deferred income taxes | 2,298,934 | | 7% | 1,131,871 | | 7% | (103%) | 3,107,884 | | 4% | 3,510,958 | | 7% | 11% |
| | | | | | | | | | | |
| Net income (loss) | (890,260 | ) | (3%) | 1,228,387 | | 7% | (172%) | 2,043,429 | | 3% | 2,211,800 | | 5% | (8%) |
| | | | | | | | | | | |
| EBITDA(Non-IFRS measure) | 4,599,642 | | 14% | 3,004,034 | | 18% | 53% | 11,349,699 | | 15% | 8,075,502 | | 17% | 41% |
| | | | | | | | | | | |
| Adjusted EBITDA(Non-IFRS measure) | 7,206,257 | | 22% | 4,554,597 | | 28% | 58% | 19,125,590 | | 25% | 12,793,514 | | 27% | 49% |
| | | | | | | | | | | |
| Annual recurring revenue(Non-IFRS measure) | 93,693,789 | | | 53,452,108 | | | 75% | 93,693,789 | | | 53,452,108 | | | 75% |
| | | | | | | | | | | |
| Term licences, maintenance and support revenue | 23,627,391 | | 74% | 13,892,323 | | 84% | 70% | 61,865,501 | | 80% | 39,396,754 | | 82% | 57% |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | As at | | | | | |
| | | | | September 30, 2025 | December 31, 2024 | | | | | |
| | | | | $ | $ | | | | | |
| | Cash balance | | | 123,684,500 | 56,574,904 | | | | | |
| | | | | | | | | | | |
| | Deferred revenue | | 54,851,879 | 35,636,002 | | | | | |
About VitalHub
VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit www.vitalhub.com and LinkedIn.
Contact Information
Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
christian.sgro@vitalhub.com
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
dan.matlow@vitalhub.com
Cautionary Statement
Certain statements contained in this news release may constitute "forward-looking information" or "financial outlook" within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
© 2025 Canjex Publishing Ltd. All rights reserved.